Atea Pharmaceuticals, Inc.

Good afternoon, everyone, and welcome to the Atea Pharmaceuticals second quarter 2026 financial results and business update conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions. I would now like to turn the call over to Jonae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Ms. Barnes, please proceed.

Thank you, operator. Good afternoon, everyone, and welcome to Atea Pharmaceuticals' second quarter 2026 financial results and business update conference call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at ir.ateafarma.com. With me from Atea are our Chief Executive Officer and Founder, Dr. Jean-Pierre Sommadossi, Chief Development Officer, Dr. Janet Hammond, Chief Commercial Officer, John Vavricka, Chief Medical Officer, Dr. Arantxa Horga, Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran, who will be available for the Q&A portion of today's call. Before we begin the call, and as outlined on slide two, I would like to remind you that today's discussion will contain forward-looking statements that involves risk and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean-Pierre.

Thank you, Jonae. Good afternoon, everyone, and thank you for joining us. I will begin on slide three. The positive top-line results from CBEYOND, our Phase III trial evaluating The combination of BAM and Rusosvir for the treatment of hepatitis C in North America represents a significant milestone for Atea and for the millions of people living with hepatitis C who need a shorter, simpler path to cure. We were very pleased that C.B. Young met both his primary and secondary endpoints with BAM and Rusosvir demonstrating Statistical non-inferiority to Abclusa, the current standard of care. Importantly, this was the first successful phase three trial in the global head-to-head HCV program achieved in the real world patient population that was poorly medicated, psychiatrically complex, substance abuse affected, and Aderence Challenge. These results reinforce the need for a best-in-class profile designed for the broad and complex hepatitis C population clinicians treated today. Arantxa will review in detail the results of the trial. See for our second phase three trial. being conducted outside North America, is fully enrolled with more than 880 patients, and we remain on track to report top-line results in early Q1, 2027. We believe that the C4 data set will provide important confirmatory efficacy data across a broader In July, we also initiated our first in-human Phase I clinical trial of AT587, our potential first-in-class direct-acting antiviral for chronic hepatitis E, a serious disease with no approved therapy today. This milestone reflects the continued advancement of our all-direct-acting antiviral pipeline. We remain in a solid financial position with $219.5 million in cash and marketable securities as of June 30, 2026. With our cash runway, anticipated through 2027. I will now hand the call over to Arantxa, our chief medical officer, to review our phase three program.